KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Accumulated Depreciation & Amortization (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 16 years of Accumulated Depreciation & Amortization data on record, last reported at $1.1 billion in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization fell 10.44% year-over-year to $1.1 billion; the TTM value through Dec 2024 reached $1.1 billion, down 10.44%, while the annual FY2024 figure was $1.1 billion, 10.44% down from the prior year.
  • Accumulated Depreciation & Amortization reached $1.1 billion in Q4 2024 per VRTX's latest filing, down from $1.2 billion in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.2 billion in Q4 2023 and bottomed at $790.6 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $993.5 million, with a median of $1.0 billion recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 639.25% in 2020, then fell 10.44% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $790.6 million in 2020, then increased by 13.34% to $896.0 million in 2021, then rose by 14.65% to $1.0 billion in 2022, then increased by 15.73% to $1.2 billion in 2023, then dropped by 10.44% to $1.1 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.1 billion in Q4 2024, $1.2 billion in Q4 2023, and $1.0 billion in Q4 2022.